SavedAdd your journal

Journals / Journal of Clinical and Analytical Medicine / 2013 / Cilt: 4 - Sayı: 3

Çoklu İlaç Direnci Gösteren Bakterilere Karşı Geliştirilen Yeni Antibiyotikler

New Antibiotics in Development Against Multidrug-Resistant Bacteria

Hüsrev DİKTAŞ
Soner YILMAZ
Pages
249–252
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, although the development of new antibiotics is soimportant, the main purpose should be determining the new targets in orderto minimize undesired effects and drug interactions, detecting new antibiotics effect mechanisms and developing new antibiotics for these purposes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The rapid development of resistance to antimicrobial agents caused to investigate new antimicrobial agents for the treatment of various infectionsand new antibiotic effect mechanisms.
📊
Key Findings & Data:Development speed of newantibacterial agents decreased dramatically in the last ten years.
💡
Conclusion & Impact:In addition, although the development of new antibiotics is soimportant, the main purpose should be determining the new targets in orderto minimize undesired effects and drug interactions, detecting new antibiotics effect mechanisms and developing new antibiotics for these purposes.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The rapid development of resistance to antimicrobial agents caused to investigate new antimicrobial agents for the treatment of various infectionsand new antibiotic effect mechanisms. Methicillin-resistant Staphylococcusaureus (MRSA), vancomycin-resistant enterococci (VRE), extended-spectrumbeta-lactamase (ESBL) Escherichia coli and Klebsiella spp., multidrug-resis- tant strains of Acinetobacter baumannii and Pseudomonas aeruginosa arethe most important targets for new antibacterial. Development speed of newantibacterial agents decreased dramatically in the last ten years. Correctuse of antibiotics should be the basic principle to avoid the development ofresistance. In addition, although the development of new antibiotics is soimportant, the main purpose should be determining the new targets in orderto minimize undesired effects and drug interactions, detecting new antibiotics effect mechanisms and developing new antibiotics for these purposes.

Özet

Antimikrobiyal ajanlara hızla direnç gelişimi, çeşitli enfeksiyonların tedavisinde yeni antimikrobiyal ajanların ve yeni etki mekanizmalarının araştırılmasına neden olmuştur. Metisiline dirençli Staphylococcus aureus (MRSA), van- komisine dirençli enterokoklar (VRE), genişlemiş spektrumlu beta laktamaz(GSBL) oluşturan Escherichia coli ve Klebsiella spp. ile çoklu ilaç direnci gösteren Acinetobacter baumannii ve Pseudomonas aeruginosa suşları yeni antibakteriyellerin en önemli hedefleridir. Son on yıl içerisinde yeni antibakteriyel ajan geliştirme hızı çarpıcı şekilde düşmektedir. Direnç gelişiminin önünegeçebilmek için doğru antibiyotik kullanımı temel ilke olmalıdır. Bunun yanın- da, her ne kadar yeni antibiyotikler önemli olsa da asıl amaç istenmeyen etkileri ve ilaç etkileşimlerini en aza indirmek için yeni hedeflerin saptanması,yeni mekanizmaların belirlenmesi ve bunlara yönelik yeni antibiyotiklerin geliştirilmesi olmalıdır.

🔖

Cite This Article

DİKTAŞ, H., YILMAZ, S. (2022). Çoklu İlaç Direnci Gösteren Bakterilere Karşı Geliştirilen Yeni Antibiyotikler. Journal of Clinical and Analytical Medicine, Cilt: 4 - Sayı: 3, 249–252. https://ajindex.com/articles/561574

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Fleming A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. British Journal of Experimental Pathology 1929
  2. Bassetti M, Ginocchio F, Mikulska M, Taramasso L, Giacobbe DR. Will new antimicrobials overcome resistance among Gram-negatives? Expert Rev Anti Infect Ther 2011
  3. 9(10):909-22. 3.Moellering RC, Jr. Advances in Antibacterial Therapy. Transplant Proc 2011
  4. 43(6):2441-2. 4.Bush K, Heep M, Macielag MJ, Noel GJ: Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007
  5. 16(4):419-29. 5.Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. Journal of Antimicrobial Chemotherapy 2008
  6. 595–602. 6.Mülazımoğlu L. 1986’dan Günümüze Karbapenemler. ANKEM Derg 2010
  7. 24(Ek 2):S33-5. 7.Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems Journal of Antimicrobial Chemotherapy 2003
  8. 538–42. 8.Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007
  9. 8(2):237-56. 9. Başaran S, Korten V. Doripenem: Klinik uygulamada yeni bir karbapenem Klimik Dergisi 2010
  10. 23(1):2-5. 10.Bush K, Macielag M, Weidner-Wells M. Taking inventory: antibacterial agents currently at or beyond Phase 1. Current Opinion in Microbiology 2004
  11. 466–76. 11.Ward KE, Mersfelder TL, LaPlante KL. Oritavancin an investigational glycopep- tide antibiotic. Expert Opin Investig Drugs 2006
  12. 15(4):417-29. 12.Öztürk R. Yeni anti-gram pozitif antibiyotikler. ANKEM Dergi 2007
  13. 21(Ek 2):S34-9 13.Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C. Dalbavan- cin: A novel once-weeklylipoglycopeptide antibiotic. Clinical Infectious Diseases 2008
  14. 577–83 14. Montecalvo MA. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. Journal of Antimicrobial Chemotherapy 2003
  15. 51(Suppl. S3):iii31–iii35. 15.George A. Pankey Tigecycline. Journal of Antimicrobial Chemotherapy 2005
  16. 470–80. 16.Ulusoy S. Tigesiklin. ANKEM Derg 2006
  17. 20(Ek 2):S117-19. 17.Townsend ML, Pound MW, Drew RH. Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia. Infection and Drug Resistance